The use of radioactive iodine has become an important adjunct to the treatment of thyroid cancer. Many normal tissues—including salivary glands, gastrointestinal mucosa, gonads, and lactating breast tissue—have the ability to concentrate radioactive iodine under normal circumstances. Although the mechanism is just beginning to be elucidated, it is this ability that might contribute to the immediate and long-term complications associated with radioactive iodine treatment. In some patients, the salivary complications can be permanent and might compromise daily functioning. In this article, we examine the salivary gland complications associated with radioactive iodine therapy, and we suggest potential protective mechanisms to circumvent these problems.
References
1.
RiceDH, BeckerTS. The Salivary Glands: Radiology, Surgery, Pathology. New York: Thieme Medical Publishers, 1994.
2.
BatsakisJG. Physiology. In: CummingsCW, SchullerDE, eds. Otolaryngology–Head and Neck Surgery. Vol. 2. St. Louis: Mosby-Year Book, 1998:1210–22.
3.
CarrascoN.Iodide transport in the thyroid gland. Biochem Biophys Acta1993;1154:65–82.
4.
DaiG, LevyO, CarrascoN.Cloning and characterization of the thyroid iodide transporter. Nature1996;379:458–60.
5.
SmanikPA, LiuQ, FurmingerTL, Cloning of the human sodium lodide [sic] symporter. Biochem Biophys Res Commun1996;226:339–45.
6.
JhiangSM, ChoJY, RyuKY, An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology1998;139:4416–9.
7.
SpitzwegC, JobaW, EisenmengerW, HeufelderAE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab1998;83:1746–51.
8.
MorrisJC, BergertER, BryantWP. Binding of immunoglobulin G from patients with autoimmune thyroid disease to rat sodium-iodide symporter peptides: Evidence for the iodide transporter as an autoantigen. Thyroid1997;7:527–34.
9.
LandisSH, MurrayT, BoldenS, WingoPA. Cancer statistics, 1998. CA Cancer J Clin1998;48:6–29.
10.
MaxonHR, SmithHS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am1990;19:685–718.
11.
SweeneyDC, JohnstonGS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am1995;24:803–39.
12.
FoxPC. Acquired salivary dysfunction. Drugs and radiation. Ann N Y Acad Sci1998;842:132–7.
13.
SchneyerLH. Effect of administration of radioactive iodine on human salivary gland function. J Dent Res1953;32:146.
RodriguesM, HavlikE, PeskarB, SinzingerH.Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy? Eur J Nucl Med1998;25:265–9.
16.
FordH, JohnsonL, PurdieG, FeekC.Effects of hyperthyroidism and radioactive iodine given to ablate the thyroid on the composition of whole stimulated saliva. Clin Endocrinol (Oxf)1997;46:189–93.
MalpaniBL, SamuelAM, RayS.Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys1996;35:535–40.
19.
BohuslavizkiKH, BrennerW, LassmanS, Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun1996;17:681–6.
20.
HallP, HolmLE, LundellG, Cancer risks in thyroid cancer patients. Br J Cancer1991;64:159–63.
21.
EdmondsCJ, SmithT.The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol1986;59:45–51.
22.
Rodriguez-CuevasS, OcampoLB. A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Eur J Surg Oncol1995;21:692.
23.
SpiegelW, ReinersC, BornerW.Sialadenitis following iodine-131 therapy for thyroid carcinoma [letter]. J Nucl Med1985;26:816–7.
24.
MaierH, BihlH.Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol1987;103:318–24.
25.
DreizenS, BrownLR, HandlerS, LevyBM. Radiation-induced xerostomia in cancer patients. Effect on salivary and serum electrolytes. Cancer1976;38:273–8.
26.
AlbrechtHH, CreutzigH.[Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy]. ROFO Fortschr Geb Rontgenstr Nuklearmed1976;125:546–51.
27.
WiesenfeldD, WebsterG, CameronF, Salivary gland dysfunction following radioactive iodine therapy. Oral Surg Oral Med Oral Pathol1983;55:138–41.
28.
KhanS, WaxmanA, RamannaL, Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC) [abstract]. J Nucl Med1994;35:15.
29.
LaupaMS, TothBB, KeeneHJ, SellinRV. Effect of radioactive iodine therapy on salivary flow rates and oral Streptococcus mutans prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol1993;75:312–7.
30.
AllweissP, BraunsteinGD, KatzA, WaxmanA.Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med1984;25:755–8.
31.
LinWY, ShenYY, WangSJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med1996;21:780–2.
32.
AlexanderC, BaderJB, SchaeferA, Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med1998:39:1551–4.
33.
Van NostrandDV, NeutzeJ, AtkinsF.Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med1986;27:1519–27.
34.
HoffmanDA, McConaheyWM, FraumeniJFJr., KurlandLT. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol1982;11:218–24.
35.
RonE, DoodyMM, BeckerDV, Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA1998;280:347–55.
36.
CreutzigH.Letter to the editor. J Nucl Med1985;26:817.
37.
LevyHA, ParkCH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med1987;12:303–7.
38.
WolffA, AtkinsonJC, MacynskiAA, FoxPC. Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monogr1990;(9):87–90.
39.
NaglerR, MarmaryY, GolanE, ChevionM.Novel protection strategy against X-ray-induced damage to salivary glands. Radiat Res1998;149:271–6.
40.
CapizziR.Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol1996;23(suppl 8):2–17.
41.
YuhasJM. Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses [sic]. Radiat Res1970;44:621–8.
42.
TannehillSP, MehtaMP. Amifostine and radiation therapy: Past, present, and future. Semin Oncol1996;23(suppl 8):69–77.
43.
BuntzelJ, KuttnerK, FrohlichD, GlatzelM.Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol1998;9:505–9.
44.
McDonaldS, MeyerowitzC, SmudzinT, RubinP.Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys1994;29:747–54.
45.
RaseyJS, GrunbaumZ, KrohnKA, Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate(WR77913). Radiat Res1985;102:130–7.
46.
BohuslavizkiKH, KlutmannS, BrennerW, Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study. J Clin Oncol1998;16:3542–9.
